What is the catalog number for MMAF (GMP)?

The catalog number for MMAF (GMP) is HY-15579G.

What sizes are available for MMAF (GMP)?

MMAF (GMP) is available in the following size(s): 1 Each.

Is MMAF (GMP) in stock?

MMAF (GMP) is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures MMAF (GMP)?

MMAF (GMP) is manufactured by QuantiMol.

What is the estimated delivery time for MMAF (GMP)?

Estimated delivery time for MMAF (GMP) is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for MMAF (GMP)?

The safety data sheet for MMAF (GMP) is available here: http://file.medchemexpress.com/batch_PDF/HY-15579G/.

MMAF (GMP)

MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A[1][2][3].

Product Specifications

CAS Number

745017-94-1

Product Name Alternative

Monomethylauristatin F (GMP)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

ADC Payload; Microtubule/Tubulin

Type

GMP Small Molecules

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mmaf-gmp.html

Solubility

10 mM in DMSO

Smiles

CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O

Molecular Formula

C39H65N5O8

Molecular Weight

731.96

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17 (1) :114-24.|[2]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16 (9) :2562-70.|[3]Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54 (41) :12020-4.|[4]Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics.